G. de Castro

发表

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients

C. Sotiriou, D. Larsimont, F. Cardoso, 2007, British Journal of Cancer.

Combining discovery and targeted proteomics reveals a prognostic signature in oral cancer

J. Fox, T. Salo, R. Minghim, 2018, Nature Communications.

KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

R. Greil, K. Harrington, A. Psyrri, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Valproic acid combined with cisplatin-based chemoradiation in locally advanced head and neck squamous cell carcinoma patients and associated biomarkers

L. Diao, G. de Castro, E. M. Nunes, 2020, Ecancermedicalscience.

Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients

G. de Castro, M. Federico, 2006, Current opinion in oncology.

Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score

R. Greil, K. Harrington, I. Braña, 2022, Journal of Clinical Oncology.

Supportive care in head and neck oncology

G. de Castro, Rodrigo SC Guindalini, R. Guindalini, 2010, Current opinion in oncology.

Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.

S. Ou, M. Varella‐Garcia, D. Camidge, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Global prevalence of human papillomavirus-driven oropharyngeal squamous cell carcinoma following the ASCO guidelines: A systematic review and meta-analysis.

L. Kowalski, T. Brandão, A. Santos‐Silva, 2020, Critical reviews in oncology/hematology.

Extraoral photobiomodulation for prevention of oral and oropharyngeal mucositis in head and neck cancer patients: interim analysis of a randomized, double-blind, clinical trial

A. Prado-Ribeiro, T. Brandão, A. Santos‐Silva, 2021, Supportive Care in Cancer.

Building research capacity and clinical trials in developing countries.

R. Arai, P. Hoff, G. de Castro, 2010, The Lancet. Oncology.

Head and neck cancer emerging strategies: advances and new challenges.

A. Awada, G. de Castro, 2009, Current opinion in oncology.

Lung Cancer in Brazil.

G. de Castro, V. C. Cordeiro de Lima, P. Ugalde, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies)

A. Awada, G. de Castro, 2006, Current opinion in oncology.

Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer

R. Riechelmann, S. Nonogaki, R. Munhoz, 2017, Ecancermedicalscience.

Survival analysis of young adults from a Brazilian cohort of non-small cell lung cancer patients

K. Ribeiro, G. de Castro, J. E. Neto, 2021, Ecancermedicalscience.

ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation.

G. de Castro, A. Ferraz, I. Snitcovsky, 2011, Oncology reports.

Extraoral photobiomodulation for prevention of oral and oropharyngeal mucositis in head and neck cancer patients: interim analysis of a randomized, double-blind, clinical trial

A. Prado-Ribeiro, T. Brandão, A. Santos‐Silva, 2021, Supportive Care in Cancer.

Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.

R. Greil, K. Harrington, I. Braña, 2022, Oral oncology.

Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC.

T. Mok, B. Karaszewska, B. Cho, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Criteria for eligibility to cisplatin in the curative treatment of head and neck cancer: Consensus opinion from a panel of experts.

G. de Castro, P. Mora, U. Nicolau, 2018, Critical reviews in oncology/hematology.

R. Herbst, M. Ahn, E. Felip, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.

P. Hoff, G. de Castro, M. Kulcsar, 2016, Thyroid : official journal of the American Thyroid Association.

Safety and efficacy of pembrolizumab (Pembro) monotherapy in elderly patients (Pts) with PD-L1-positive advanced NSCLC: Pooled analysis from KEYNOTE-010, -024, and -042.

Y. Hosomi, H. Saka, E. Felip, 2019, Annals of Oncology.

Predicting survival in metastatic non‐small cell lung cancer patients with poor ECOG‐PS: A single‐arm prospective study

A. Fujita, G. de Castro, M. Cunha, 2022, Cancer medicine.

NEPTUNE: Phase III Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC.

Ying Cheng, K. Syrigos, N. Rizvi, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Oral mucositis prevention by low-level laser therapy in head-and-neck cancer patients undergoing concurrent chemoradiotherapy: a phase III randomized study.

G. de Castro, M. Federico, E. Gil, 2012, International journal of radiation oncology, biology, physics.

Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30.

P. Fayers, M. King, M. Martyn St-James, 2012, European journal of cancer.

A phase 2 study of first‐line nivolumab in patients with locally advanced or metastatic cutaneous squamous‐cell carcinoma

R. Munhoz, F. Franke, G. de Castro, 2022, Cancer.

LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042

J. Lunceford, M. Ayers, R. Herbst, 2019 .

Exercise prescription for symptoms and quality of life improvements in lung cancer patients: a systematic review

G. de Castro, Ana Paula de Souza Borges, A. Codima, 2020, Supportive Care in Cancer.

P. Hoff, G. de Castro, T. K. Takahashi, 2017, Journal of global oncology.

Impact of radiation on tooth loss in patients with head and neck cancer: a retrospective dosimetric-based study.

T. Brandão, C. Rivera, J. Epstein, 2021, Oral surgery, oral medicine, oral pathology and oral radiology.

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study

R. Greil, I. Braña, A. Psyrri, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes in KEYNOTE-042: Pembrolizumab Versus Chemotherapy For Advanced PD-L1 Positive NSCLC.

J. Lunceford, M. Ayers, T. Mok, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer *

G. de Castro, G. Lopes, Edoardo F. Q. Vattimo, 2015, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia.

Oral leukoplakia and erythroplakia in young patients: a systematic review.

L. Kowalski, T. Brandão, M. Lopes, 2020, Oral surgery, oral medicine, oral pathology and oral radiology.

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.

Ulrich Keilholz, Thomas Gauler, J. Machiels, 2015, The Lancet. Oncology.

Review: side effects of approved molecular targeted therapies in solid cancers.

Phuong Dinh, A. Awada, E. de Azambuja, 2007, The oncologist.

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study

T. Mok, I. Bondarenko, B. Karaszewska, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

De-escalation treatment of human papillomavirus-positive oropharyngeal squamous cell carcinoma: an evidence-based review for the locally advanced disease

G. de Castro, R. Bonadio, G. Stock, 2018, Current opinion in oncology.

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial

Y. Shentu, R. Herbst, M. Ahn, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer.

Yi-long Wu, J. Rigas, Yuh-Min Chen, 2019, Future oncology.

Targeting the immune system in head and neck cancer.

G. de Castro, P. Isaacsson Velho, 2015, Current opinion in oncology.

The role of single-nucleotide polymorphism (SNPs) in toxicity of induction chemotherapy based on cisplatin and paclitaxel in patients with advanced head and neck cancer.

A. Carvalho, R. Reis, M. Melendez, 2019, Oral oncology.

Cystic brain metastases in ALK-rearranged non-small cell lung cancer

G. de Castro, R. E. Martins, H. Zuppani, 2018, Ecancermedicalscience.

Comprehensive genomic profiling of Brazilian non‐small cell lung cancer patients (GBOT 0118/LACOG0418)

G. Werutsky, G. de Castro, C. Mathias, 2020, Thoracic cancer.

BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?

C. Rolfo, L. Raez, R. Caparica, 2016, Critical reviews in oncology/hematology.

Assessing Oncologists’ Attitudes Concerning Comprehensive Genomic Profiling in Stage IV Lung Adenocarcinoma in Brazil

G. Werutsky, G. de Castro, T. E. Colombo, 2022, JTO clinical and research reports.

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042

A. Mansfield, R. Herbst, T. Mok, 2021, JTO clinical and research reports.

Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03)

J. Bosch-Barrera, L. Ciuffreda, G. de Castro, 2021, Therapeutic advances in medical oncology.

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations

G. Lopes, B. Haaland, G. de Castro, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Impact of the COVID-19 Pandemic on Oncology Clinical Research in Latin America (LACOG 0420)

C. Barrios, A. Cardona, W. William, 2021, JCO Global Oncology.

Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.

Y. Hosomi, Yi-long Wu, H. Saka, 2019, Lung cancer.

1064P Final results of CA209-9JC: A phase II study of first-line nivolumab in patients with advanced cutaneous squamous cell carcinoma

F. Franke, G. de Castro, J. Cury-Martins, 2021, Annals of Oncology.

Non-gastrointestinal stromal tumours soft tissue sarcomas: an update

R. Munhoz, G. de Castro, G. Matos, 2019, Ecancermedicalscience.

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.

C. Schumann, M. Socinski, R. Kurek, 2015, The Lancet. Oncology.

Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer

R. Barroso-Sousa, G. de Castro, K. T. Souza, 2014, Medical Oncology.

Cisplatin based chemoradiation late toxicities in head and neck squamous cell carcinoma patients.

G. de Castro, M. Mak, R. E. Martins, 2015, Discovery medicine.

An Open‐Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC‐A12) as a First‐Line Therapy in Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer

Tuan S. Nguyen, G. Scagliotti, S. Novello, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Molecular targets for therapeutic interventions in human papillomavirus-related cancers (review).

P. Hoff, G. de Castro, A. Talans, 2010, Oncology reports.

An integrated approach for tailored treatment in breast cancer.

A. Awada, G. de Castro, G. D. Castro, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Palliative chemotherapy outcomes in patients with ECOG-PS higher than 1

P. Hoff, G. de Castro, M. Mak, 2018, Ecancermedicalscience.

Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer: A Retrospective Analysis

G. de Castro, M. Mak, T. K. Takahashi, 2017, Journal of global oncology.

Successful osimertinib rechallenge following drug-induced pneumonitis after previous anti-PDL1 exposure

G. de Castro, F. Santini, G. Harada, 2019, Ecancermedicalscience.

Plasma osteopontin levels in patients with head and neck cancer undergoing chemoradiotherapy.

G. Leitão, G. de Castro, S. Maistro, 2009, Archives of otolaryngology--head & neck surgery.

Management of advanced head and neck squamous cell carcinoma in elderly patients.

A. Awada, G. de Castro, 2006, Current opinion in oncology.

Meta-omics analysis indicates the saliva microbiome and its proteins associated with the prognosis of oral cancer patients.

F. Squina, A. Prado-Ribeiro, T. Brandão, 2021, Biochimica et biophysica acta. Proteins and proteomics.

NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer.

N. Shire, Jian-hua Chang, Si Sun, 2023, Lung cancer.

Combining discovery and targeted proteomics reveals a prognostic signature in oral cancer

R. Minghim, N. Cervigne, T. Brandão, 2018, Nature Communications.

Economic analyses in squamous cell carcinoma of the head and neck: a review of the literature from a clinical perspective.

Ya-Chen Tina Shih, J. D. de Souza, G. de Castro, 2014, International journal of radiation oncology, biology, physics.

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.

Y. Shentu, R. Herbst, M. Ahn, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study.

P. Postmus, Keunchil Park, R. Dziadziuszko, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The influence of a supervised group exercise intervention combined with active lifestyle recommendations on breast cancer survivors’ health, physical functioning, and quality of life indices: study protocol for a randomized and controlled trial

C. Ugrinowitsch, G. de Castro, P. Brum, 2021, Trials.

Second primary cancers in head and neck cancer patients: a challenging entity.

A. Awada, G. de Castro, 2012, Current opinion in oncology.

Impact of pandemic COVID-19 outbreak on oral mucositis preventive and treatment protocols: new perspectives for extraoral photobiomodulation therapy

L. Kowalski, A. Prado-Ribeiro, T. Brandão, 2020, Supportive Care in Cancer.

Serum Creatinine as a Potential Biomarker of Skeletal Muscle Atrophy in Non-small Cell Lung Cancer Patients

G. de Castro, Christiano R. R. Alves, Willian das Neves, 2021, Frontiers in Physiology.

ATAC trial update.

G. de Castro, 2005, The Lancet.

Shrinking the tumor, shrinking the patient sample size: the early disclosure dilemma.

F. Puglisi, E. de Azambuja, G. de Castro, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.